Lead Product(s) : Benegrastim
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Evive Biotech
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Aurobindo Unit, Evive Biotech Ink Licensing Pact to Commercialise CIN Treatment Product in US
Details : Under the terms of the agreement, Evive will be responsible for the ongoing development, manufacturing, registration, and supply of Ryzneuta (benegrastim), while Acrotech will use its sales and commercialisation capabilities to market and distribute the ...
Product Name : Ryzneuta
Product Type : Protein
Upfront Cash : Undisclosed
November 23, 2022
Lead Product(s) : Benegrastim
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Evive Biotech
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Desidustat
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : China Medical System Holdings Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Zydus inks pact with China Medical System to market Desidustat in Greater China
Details : Under the terms and conditions of the agreement, CMS will be responsible for development, registration and commercialisation of Desidustat in Greater China.
Product Name : Oxemia
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 20, 2020
Lead Product(s) : Desidustat
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : China Medical System Holdings Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement